News - Roche

Filter

Current filters:

Roche

Popular Filters

51 to 75 of 370 results

Avastin seen to prolong life for women with advanced cervical cancer

Avastin seen to prolong life for women with advanced cervical cancer

20-02-2014

Swiss drug major Roche’s blockbuster cancer drug Avastin (bevacizumab) can extend the lives of women…

AvastinOncologyPharmaceuticalResearchRoche

Roche’s breast cancer drug Kadcyla debuts in UK

Roche’s breast cancer drug Kadcyla debuts in UK

13-02-2014

Swiss drug major Roche’s Kadcyla (ado-trastuzumab emtansine or T-DM1) is now available for UK patients…

KadcylaMarkets & MarketingNorthern EuropeOncologyPharmaceuticalRocheUK

UK’s NICE consults on updating guidance for Tarceva and Iressa

UK’s NICE consults on updating guidance for Tarceva and Iressa

04-02-2014

The UK’s National Institute for Health and Care Excellence (NICE) said this morning that it is reviewing…

AstraZenecadocetaxelIressaOncologyPharmaceuticalRegulationRocheTarcevaUK

PDL BioPharma settles litigation with Genentech and Roche

03-02-2014

US drugmaker PDL BioPharma has entered into an agreement with Genentech and its parent, Swiss drug major…

BiotechnologyFinancialGenentechLegalOncologyOphthalmicsPDL BioPharmaRoche

Mylan debuts Hertraz, first Herceptin biosimilar, in India

Mylan debuts Hertraz, first Herceptin biosimilar, in India

03-02-2014

US generics major Mylan has launched the world's first trastuzumab biosimilar in India. The product,…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazIndiaMarkets & MarketingMylan LaboratoriesOncologyRoche

Roche sees strong 2013 sales growth, but still disappoints

Roche sees strong 2013 sales growth, but still disappoints

30-01-2014

Swiss drug major Roche posted full-year 2013 financial results this morning, showing that group sales…

FinancialRoche

UK’s NICE gives green light to Roche’s MabThera for GPA and MPA

UK’s NICE gives green light to Roche’s MabThera for GPA and MPA

24-01-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) today approved the use…

EuropeImmunologicalsMabTheraPharmaceuticalPricingRegulationRocheUK

Prothena to get $30 million upfront from Roche triggered by regulatory milestone

Prothena to get $30 million upfront from Roche triggered by regulatory milestone

23-01-2014

Clinical-stage biotech firm Prothena said today that it will receive the $30 million upfront payment…

BiotechnologyFinancialLicensingNeurologicalProthenaPRX002Roche

Disappointing results for Roche in Phase III schizophrenia studies

Disappointing results for Roche in Phase III schizophrenia studies

21-01-2014

Swiss drug major Roche (ROG: SIX) has revealed disappointing results from two Phase III studies of its…

bitopertinNeurologicalNorthern EuropePharmaceuticalResearchRoche

MAb market for gastric and esophageal cancer expected to double by 2019

MAb market for gastric and esophageal cancer expected to double by 2019

18-01-2014

Due to favorable market conditions in terms of US pricing structures and the anticipated approval of…

BiotechnologyHerceptinMarkets & MarketingOncologyRoche

Breakthrough year for unmet diseases, as FDA backs 37 designations in 2013

Breakthrough year for unmet diseases, as FDA backs 37 designations in 2013

17-01-2014

Since the US Food and Drug Administration’s breakthrough therapy designation (BTD) was put into effect…

GazyvaGilead SciencesImbruvicaJohnson & JohnsonPharmaceuticalRegulationRocheSovaldiUSA

Celltrion’s trastuzumab biosimilar, Herzuma, approved in South Korea

16-01-2014

South Korean biopharmaceutical firm Celltrion has received approval for its cancer treatment biosimilar…

Asia-PacificBiosimilarsCellTrionGenericsHerceptinHerzumaOncologyRegulationRoche

Santaris inks deal with Roche for RNA-targeted medicines

Santaris inks deal with Roche for RNA-targeted medicines

09-01-2014

Danish privately held clinical-stage biopharmaceutical company Santaris Pharma has signed a worldwide…

LicensingPharmaceuticalResearchRocheSantaris Pharma

Lung cancer treatment takes another forward step in New Zealand

Lung cancer treatment takes another forward step in New Zealand

09-01-2014

Improvements in lung cancer treatment are set to continue with a decision for New Zealand’s Pharmaceutical…

Asia-PacificAstraZenecaFinancialHealthcareIressaOncologyPharmaceuticalRocheTarceva

UK MPs express concerns on clinical trial data transparency and Tamiflu stockpiling

UK MPs express concerns on clinical trial data transparency and Tamiflu stockpiling

06-01-2014

The UK House of Commons Public Accounts Committee is calling for all data on drugs being prescribed in…

Anti-viralsNorthern EuropePharmaceuticalRegulationResearchRocheTamifluUK

Chugai signs deal to set up China subsidiary

31-12-2013

Japanese drugmaker Chugai Pharmaceutical, which is majority-owned by Swiss drug major Roche, says it…

Asia-PacificChinaChugai PharmaceuticalMarkets & MarketingPharmaceuticalRoche

IQWiG view on Roche’s Zelboraf unchanged despite new data

IQWiG view on Roche’s Zelboraf unchanged despite new data

18-12-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) has reassessed Swiss drug major…

EuropeOncologyPharmaceuticalPricingRegulationRocheZelboraf

Prothena inks deal with Roche, worth a potential $600 million

Prothena inks deal with Roche, worth a potential $600 million

12-12-2013

Biotech firm Prothena has entered into a worldwide collaboration with Swiss drug major Roche to develop…

BiotechnologyGlobalLicensingNeurologicalProthenaPRX002ResearchRoche

Roche board of directors to be decided at AGM in March

Roche board of directors to be decided at AGM in March

10-12-2013

Swiss drug major Roche (ROG: SIX) has issued a list of members of the Board of Directors to be elected…

BoardroomNorthern EuropePharmaceuticalRoche

51 to 75 of 370 results

Back to top